Spark Therapeutics, Inc. Common Stock
ONCE
ONCE was delisted on the 16th of December, 2019.
184 hedge funds and large institutions have $3.45B invested in Spark Therapeutics, Inc. Common Stock in 2019 Q3 according to their latest regulatory filings, with 24 funds opening new positions, 63 increasing their positions, 56 reducing their positions, and 34 closing their positions.
15% more funds holding in top 10
Funds holding in top 10: 20 → 23 (+3)
13% more repeat investments, than reductions
Existing positions increased: 63 | Existing positions reduced: 56
5% more capital inflows, than outflows
Capital inflows: $615M | Capital outflows: $587M
0.64% more ownership
Funds ownership: 91.66% → 92.3% (+0.64%)
5% less funds holding
Funds holding: 194 → 184 (-10)
29% less first-time investments, than exits
New positions opened: 24 | Existing positions closed: 34
47% less call options, than puts
Call options by funds: $109M | Put options by funds: $204M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Pentwater Capital Management
Naples,
Florida
|
+$133M |
| 2 |
BC
Boxer Capital
San Diego,
California
|
+$105M |
| 3 |
PC
Paulson & Co
New York
|
+$68.1M |
| 4 |
PAM
PSquared Asset Management
Zurich,
Switzerland
|
+$27M |
| 5 |
Armistice Capital
New York
|
+$18.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Farallon Capital Management
San Francisco,
California
|
-$55.1M |
| 2 |
Renaissance Technologies
New York
|
-$39.9M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$38.7M |
| 4 |
SAM
Sandell Asset Management
New York
|
-$27.6M |
| 5 |
D.E. Shaw & Co
New York
|
-$27M |
ONCE Hedge Fund Activity: Q3 2019 in Review
184 of the 4,576 institutional investors tracked by Wall St. Rank reported a position in Spark Therapeutics, Inc. Common Stock (ONCE) for Q3 2019, worth a combined $3.45B — down 4.4% from $3.6B a quarter earlier.
Sellers outnumbered buyers: 34 funds closed out of ONCE and 24 opened new positions — a net loss of 10 holders — while 56 trimmed existing stakes and 63 added.
The largest buyer was Pentwater Capital Management, adding an estimated $133M. The largest seller was Farallon Capital Management, cutting an estimated $55.1M.
- 184 institutional investors held Spark Therapeutics, Inc. Common Stock (ONCE) as of Q3 2019, down from 194 in Q2 2019.
- Funds reported $3.45B of Spark Therapeutics, Inc. Common Stock stock for Q3 2019, down 4.4% quarter-over-quarter.
- 24 funds opened new Spark Therapeutics, Inc. Common Stock positions in Q3 2019 and 34 closed out, a net change of -10 holders.
- The largest Spark Therapeutics, Inc. Common Stock buyer in Q3 2019 was Pentwater Capital Management, an estimated $133M added.
- The largest Spark Therapeutics, Inc. Common Stock seller in Q3 2019 was Farallon Capital Management, an estimated $55.1M sold.
Based on aggregated 13F filings for Q3 2019.